APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO PREDICT ONDANSETRON PHARMACOKINETICS IN CHILDREN

被引：0
|
作者：
Zhou, W. [1 ]
Johnson, T. [2 ]
Bui, K. [1 ]
Cheung, A. [3 ]
Li, J. [1 ]
Xu, H. [1 ]
Al-Huniti, N. [1 ]
Zhou, D. [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
[2] Certara, Sheffield, S Yorkshire, England
[3] AstraZeneca, Cambridge, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-155
引用
收藏
页码：S94 / S95
页数：2
相关论文
共 50 条
  • [41] Physiologically based pharmacokinetic (PBPK) modeling and simulation: Applications in lead optimization
    Peters, Sheila Annie
    Ungell, Anna-Lena
    Dolgos, Hugues
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (04) : 509 - 518
  • [42] Physiologically based pharmacokinetic (PBPK) modeling of perfluorohexane sulfonate (PFHxS) in humans
    Sweeney, Lisa M.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2022, 129
  • [43] Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
    Cuello, W. S.
    Janes, T. A. T.
    Jessee, J. M.
    Venecek, M. A.
    Sawyer, M. E.
    Eklund, C. R.
    Evans, M. V.
    JOURNAL OF TOXICOLOGY, 2012, 2012
  • [44] Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges
    Fairman, Kiara
    Li, Miao
    Ning, Baitang
    Lumen, Annie
    BIOCHEMICAL PHARMACOLOGY, 2021, 189
  • [45] Physiologically-Based Pharmacokinetic Modeling of Omalizumab to Predict the Pharmacokinetics and Pharmacodynamics in Pediatric Patients
    Guo, Guimu
    You, Xiang
    Wu, Wanhong
    Chen, Jiarui
    Ke, Meng
    Lin, Rongfang
    Huang, Pinfang
    Lin, Cuihong
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (03) : 724 - 734
  • [46] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY
    Kyler, K.
    Shakhnovich, V.
    Selvarangan, R.
    Sasidharan, A.
    Chan, S.
    Artz, N.
    Williams, V.
    Friesen, C.
    Pearce, R.
    Gaedigk, A.
    Leeder, J.
    Galetin, A.
    Johnson, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S107
  • [47] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [48] Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
    Yang, Raymond S. H.
    Chang, Louis W.
    Yang, Chung Shi
    Lin, Pinpin
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (12) : 8482 - 8490
  • [49] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO PREDICT THE IMPACT OF CYP2D6 POLYMORPHISMS ON VELIPARIB PHARMACOKINETICS FROM IN VITRO DATA.
    Li, J.
    Wu, J.
    LoRusso, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S51 - S51
  • [50] Physiologically Based Pharmacokinetic (PBPK) Models for Ethanol
    Plawecki, Martin H.
    Han, Jae-Joon
    Doerschuk, Peter C.
    Ramchandani, Vijay A.
    O'Connor, Sean J.
    IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2008, 55 (12) : 2691 - 2700
12345